<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175327</url>
  </required_header>
  <id_info>
    <org_study_id>GLRA-G010</org_study_id>
    <nct_id>NCT04175327</nct_id>
  </id_info>
  <brief_title>CardioCel 3D Registry</brief_title>
  <official_title>Post-Market Registry in Europe for the Use of CardioCel®, CardioCel® Neo and CardioCel® 3D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Admedus Regen Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Factory CRO for Medical Devices B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Admedus Regen Pty Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-market, prospective, multi-centre, open-label, registry designed to collect prospective&#xD;
      safety and performance data on the use of CardioCel in patients with cardiovascular disorders&#xD;
      and in accordance with local standard of care.&#xD;
&#xD;
      The Registry will collect data with a minimum of 50 subjects per major indication (minimum&#xD;
      total of 200) in 5-10 sites in Europe. The clinical investigation will maintain data for each&#xD;
      patient from the date of implant through 2 years post-implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-market, prospective, multi-centre, open-label, registry designed to collect prospective&#xD;
      safety and performance data on the use of CardioCel in patients with cardiovascular disorders&#xD;
      and in accordance with local standard of care. The Registry has been designed to collect&#xD;
      prospective product safety and performance data after the CardioCel line extension for&#xD;
      CardioCel 3D and the indication expansion to include great vessel and peripheral&#xD;
      reconstruction and suture line buttressing and will collect safety and performance data up to&#xD;
      2 years following implantation. The CardioCel 3D Registry will collect data on the use of the&#xD;
      CardioCel,&#xD;
&#xD;
      CardioCel Neo and CardioCel 3D for the following major indications:&#xD;
&#xD;
        -  Intracardiac and septal defects&#xD;
&#xD;
        -  Valve and annulus repair&#xD;
&#xD;
        -  Great vessel reconstruction&#xD;
&#xD;
        -  Peripheral vascular reconstruction&#xD;
&#xD;
      As suture line buttressing is a procedure that does not consistently use tissue, data on this&#xD;
      indication will only be included if available. Data will be prospectively collected by the&#xD;
      sites on registry-specific electronic case report forms (eCRFs). The primary endpoints will&#xD;
      assess devices' safety and performance through measures and images obtained via the&#xD;
      facility's standard of care at the respective registry site. Additional data will also be&#xD;
      collected from the implant procedure to assess user (surgeon) satisfaction with the devices'&#xD;
      handling and performance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of graft related reintervention</measure>
    <time_frame>30 days post procedure.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of patch related morbidity</measure>
    <time_frame>30 days post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft related reinterventions</measure>
    <time_frame>at 1 and 2 years post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Valvular Regurgitation Grade &gt; Moderate</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>for Valve and annulus repair</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of re-stenosis</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
    <description>for Great vessel reconstruction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of recoarctation</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
    <description>for Great vessel reconstruction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of measurement of the dynamic flow by facility standard of care ≥110-175* cm/sec for peripheral vascular locations</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
    <description>for Peripheral vascular reconstruction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of Patch dehiscence</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Patch calcification</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Patch retraction</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Unanticipated events</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Intracardiac and Septal Defects</condition>
  <condition>Valve and Anulus Repair</condition>
  <condition>Great Vessel Reconstruction</condition>
  <condition>Peripheral Vessel Reconstruction</condition>
  <condition>Suture Line Buttressing</condition>
  <arm_group>
    <arm_group_label>CardioCel group</arm_group_label>
    <description>Patients who require repair of cardiac and vascular defects including intracardiac defects; septal defects, valve and annulus repair; great vessel reconstruction, peripheral vascular reconstruction and suture line buttressing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardioCel implantation</intervention_name>
    <description>treatment of intracardiac defects; treatment of septal defects; valve and annulus repair; great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing</description>
    <arm_group_label>CardioCel group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CardioCel, CardioCel Neo and CardioCel 3D are indicated for the repair of cardiac and&#xD;
        vascular defects including intracardiac defects; septal defects, valve and annulus repair;&#xD;
        great vessel reconstruction, peripheral vascular reconstruction and suture line&#xD;
        buttressing.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient has signed the informed consent&#xD;
&#xD;
          -  patient is a candidate for treatment with CardioCel/CardioCel Neo/CardioCel 3D per&#xD;
             approved device indications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - no study specific exclusion criteria; patients treated per standard clinical practice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ioana Ghiu</last_name>
    <role>Study Director</role>
    <affiliation>Anteris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avania CRO</last_name>
    <phone>+31 30 229 2727</phone>
    <email>jurriaan.sombeek@avaniaclinical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ioana Ghiu</last_name>
    <phone>+1 612 219 6032</phone>
    <email>dlinden@anteristech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcel Vollroth, Dr</last_name>
      <phone>+ 49 341 45291003</phone>
      <email>Marcel.Vollroth@helios-gesundheit.de</email>
    </contact>
    <contact_backup>
      <last_name>Robby Schurzmann</last_name>
      <email>Robby.Schurzmann@leipzig-heart.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Kostelka, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcel Vollroth, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Binner, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>MI</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Giamberti, Prof</last_name>
      <email>alessandro.giamberti@grupposandonato.it</email>
    </contact>
    <contact_backup>
      <last_name>Carmelina Chiarello</last_name>
      <phone>02 5277 4378</phone>
      <email>Carmelina.Chiarello@grupposandonato.it</email>
    </contact_backup>
    <investigator>
      <last_name>Alessandro Giamberti, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Varrica, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauro Rinaldi, Prof</last_name>
      <email>mauro.rinaldi@unito.it</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Calia, Dr</last_name>
      <email>claudiacalia92@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mauro Rinaldi, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Calia, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Doce de Octubre&quot;</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorenzo Boni, Dr</last_name>
      <email>dott.l.boni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lorenzo Boni, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Children's Hospital and the Heart Institute</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Caputo, Mr</last_name>
      <email>M.Caputo@bristol.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Karen Sheehan</last_name>
      <phone>+44 01173428889</phone>
      <email>Karen.Sheehan@uhbw.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Massimo Caputo, Mr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Parry, Mr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shafi Mussa, Mr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Nassar, Mr</last_name>
      <phone>+44 0191 2448332</phone>
      <email>Mohamed.Nassar2@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Katherine Cullen</last_name>
      <phone>+44 0191 2137746</phone>
      <email>katherinecullen@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamed Nassar, Mr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Poland</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Septal Defects</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

